Medicine
Zevtera 667 mg powder for injection
Zevtera 667 mg powder for injection is a prescription medicine containing Ceftobiprole medocaril for intravenous use, marketed by La Jolla Pharmaceutical, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store ZEVTERA vials refrigerated at 2 °C to 8 °C (36 °F to 46 °F) protected…
Key facts
- Active ingredient (INN)
- Ceftobiprole medocaril
- Brand
- Zevtera
- Strength
- 667 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 10 vials
- Marketing authorisation holder
- La Jolla Pharmaceutical
- Manufacturer
- La Jolla Pharmaceutical
- Origin register
- US FDA, United States
- Storage
- Store ZEVTERA vials refrigerated at 2 °C to 8 °C (36 °F to 46 °F) protected from light. Store in carton until time of use. Store reconstituted and diluted solution of ZEVTERA as described elsewhere in the labeling.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 April 2025
- Identifiers
- DailyMed set ID 2bd685df-7dc6-78a6-e063-6294a90a580bNDC 68547-578Application NDA218275
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 vial, glass in 1 box / 1 injection, powder, for solution in 1 vial, glass | 68547-578-10 | La Jolla Pharmaceutical | 1 April 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 3 April 2024 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Ceftobiprole medocaril is a cephalosporin antibacterial indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis, among other approved uses. MedsAcross supplies Ceftobiprole medocaril for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Ceftobiprole medocarilFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZEVTERA prescribing information (La Jolla Pharmaceutical) · U.S. National Library of Medicine, DailyMed
Need Zevtera 667 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.